|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Loxo_Oncology
|
|
gptkbp:awards
|
gptkb:Innovative_Medicines_Initiative
Best Places to Work
Top 10 Biotech Companies
|
|
gptkbp:CEO
|
Amit_K._Munshi
|
|
gptkbp:clinicalTrials
|
gptkb:Asia
gptkb:United_States
Europe
Phase 1
Phase 2
Phase 3
NCT03025256
NCT03635719
NCT04116624
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:Massachusetts_Institute_of_Technology
gptkb:Dana-Farber_Cancer_Institute
|
|
gptkbp:employees
|
over 200
|
|
gptkbp:financials
|
publicly traded
|
|
gptkbp:focus
|
targeted therapies for genomically defined cancers
|
|
gptkbp:founded
|
2008
|
|
gptkbp:founder
|
Amit_K._Munshi
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Blueprint Medicines
|
|
gptkbp:investmentFocus
|
Institutional investors
Public investors
Venture capital firms
|
|
gptkbp:leads
|
Ayvakit
BLU-667
BLU-782
BLU-554
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
gptkb:Celerion
Foundation Medicine
|
|
gptkbp:products
|
Ayvakit
BLU-667
BLU-782
BLU-554
|
|
gptkbp:regulatoryCompliance
|
EMA_approval_for_Ayvakit
FDA_approval_for_Ayvakit
|
|
gptkbp:research_areas
|
oncology
rare diseases
hematology
|
|
gptkbp:researchFocus
|
precision medicine
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
BPMC
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:tributaryOf
|
multiple drug candidates
|
|
gptkbp:website
|
www.blueprintmedicines.com
|